Paravasthu Mukund — SEC Form 4 filings
SEC reporting owner CIK 2039078. 12 Form 4 filings on record with FilingPulse; latest filed 2026-03-05.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-11-04 to 2026-03-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 9 filings — 57,820 shares, $849,760 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 43,246 shares @ $13.77 ($595,670) in NovoCure Ltd, filed 2026-03-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NovoCure Ltd (NVCR) | Chief Operating Officer | 12 | — | 15 legs · 57,820 sh · $849,760 | 10 |
Form 4 filings — Paravasthu Mukund
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-05 | 4 | NovoCure Ltd (NVCR) | Grant/award (A): 45,112 @ $0 · Sale (S): 5,377 @ $13.31 · Sale (S): 43,246 @ $13.77 · Grant/award (A): 7,518 (derivative) @ $0 · Grant/award (A): 58,488 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | NovoCure Ltd (NVCR) | Sale (S): 1,555 @ $13.66 · Sale (S): 408 @ $13.49 | EDGAR |
| 2026-01-12 | 4 | NovoCure Ltd (NVCR) | Tax withholding (F): 2,133 @ $14.35 | EDGAR |
| 2025-11-04 | 4 | NovoCure Ltd (NVCR) | Tax withholding (F): 168 @ $12.81 · Tax withholding (F): 2,949 @ $12.23 | EDGAR |
| 2025-05-05 | 4 | NovoCure Ltd (NVCR) | Sale (S): 592 @ $17.91 | EDGAR |
| 2025-03-06 | 4 | NovoCure Ltd (NVCR) | Grant/award (A): 54,975 @ $18.19 · Grant/award (A): 81,499 (derivative) @ $18.19 | EDGAR |
| 2025-03-04 | 4 | NovoCure Ltd (NVCR) | Sale (S): 250 @ $18.54 | EDGAR |
| 2025-03-03 | 4/A | NovoCure Ltd (NVCR) | Sale (S): 1,379 @ $19.92 · Sale (S): 267 @ $20.55 · Sale (S): 368 @ $18.28 | EDGAR |
| 2025-03-03 | 4 | NovoCure Ltd (NVCR) | Sale (S): 1,379 @ $19.92 · Sale (S): 267 @ $20.55 · Sale (S): 368 @ $18.28 | EDGAR |
| 2025-01-15 | 4 | NovoCure Ltd (NVCR) | Sale (S): 2,160 @ $26.81 | EDGAR |
| 2024-11-06 | 4 | NovoCure Ltd (NVCR) | Sale (S): 44 @ $16.69 · Grant/award (A): 30,138 @ $0 · Grant/award (A): 45,620 (derivative) @ $16.59 | EDGAR |
| 2024-11-04 | 4 | NovoCure Ltd (NVCR) | Sale (S): 160 @ $15.88 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2039078 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →